Address
Email address
Phone number
Website
Elite erakliinik Tartus Sangla 63. Viljatusravi ja günekoloogid, 3D-4D ultraheli, endokrinoloog, nahaarstid, kõrva-nina-kurguarstid, onkoloogid jpm. erialad
Name
OÜ FERTIILSUSE KESKUS
Registry code
10240426
VAT number
EE100042861
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
11.07.1997 (27)
Financial year
01.01-31.12
Capital
22 369.00 €
Activity
74901 - Other professional, scientific and technical activities n.e.c. 68201 - Rental and operating of own or leased real estate
1 345 372 €
638 765 €
47%
1 221 €
(estimate is approximate)
4 874 438 €
3
Submitted
No tax arrears
13%
11%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Andrei Sõritsa 25.11.1961 (62) | 100% - 22 369.00 EUR | Board member | Direct ownership | Founder |
Deniss Sõritsa 16.11.1982 (42) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member |
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
OÜ Nordik Eksperdid 11059634 | 100% - 2 556.00 EUR | - | - | |
Fabula Invest OÜ 12349446 | 100% - 2 500.00 EUR | - | - | |
Formosus Capital OÜ 12746975 | 100% - 2 500.00 EUR | - | - | |
OÜ Asper Biolab 11538286 | 50% - 20 000.00 EEK | - | - | |
Tartu linn, Munga tn 3 korteriühistu 80432340 | - | - | - | Founder (without contribution) |
OÜ Apteek Elite 10850722 | - | - | - | Founder |
2019 29.06.2020 | 2020 30.06.2021 | 2021 28.06.2022 | 2022 29.06.2023 | 2023 28.06.2024 | |
---|---|---|---|---|---|
Total Revenue | 1 152 843 € | 1 141 956 € | 1 511 834 € | 1 734 941 € | 1 345 372 € |
Net profit (loss) for the period | 666 187 € | 407 516 € | 935 230 € | 1 095 028 € | 638 765 € |
Profit Margin | 58% | 36% | 62% | 63% | 47% |
Current Assets | 478 577 € | 449 584 € | 768 254 € | 509 809 € | 441 283 € |
Fixed Assets | 3 716 408 € | 3 693 904 € | 3 756 675 € | 4 734 658 € | 5 358 367 € |
Total Assets | 4 194 985 € | 4 143 488 € | 4 524 929 € | 5 244 467 € | 5 799 650 € |
Current Liabilities | 60 086 € | 220 480 € | 248 010 € | 204 165 € | 400 461 € |
Non Current Liabilities | 287 000 € | 467 593 € | 436 274 € | 354 629 € | 524 751 € |
Total Liabilities | 347 086 € | 688 073 € | 684 284 € | 558 794 € | 925 212 € |
Share Capital | - | - | - | - | - |
Equity | 3 847 899 € | 3 455 415 € | 3 840 645 € | 4 685 673 € | 4 874 438 € |
Employees | 0 | 0 | 1 | 2 | 3 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | 176 168.5 € | 62 920.31 € | 18 204.55 € | 3 |
2023 Q4 | 161 597.67 € | 44 078.24 € | 15 667.68 € | 3 |
2023 Q3 | 44 364.45 € | 30 130.84 € | 11 894.54 € | 3 |
2023 Q2 | 317 109.22 € | 21 397.22 € | 7 857.8 € | 4 |
2023 Q1 | 60 014.31 € | 38 632.49 € | 12 624.47 € | 2 |
2022 Q4 | 127 424.16 € | 4 433.62 € | 10 028.37 € | 2 |
2022 Q3 | 242 804.66 € | - | 8 569.95 € | 2 |
2022 Q2 | 183 876.93 € | - | 1 473.06 € | 2 |
2022 Q1 | 184 267.67 € | 22 015.87 € | 6 045.62 € | 2 |
2021 Q4 | 170 658.18 € | 42 728.14 € | 12 211.57 € | 1 |
2021 Q3 | 235 153.74 € | 10 996.2 € | 2 311.58 € | 1 |
2021 Q2 | 189 854.74 € | 34 648.14 € | 9 738.66 € | 1 |
2021 Q1 | 22 609.94 € | 57 085.12 € | 8 668.51 € | 1 |
2020 Q4 | 142 690.79 € | 90 837.16 € | 8 013.49 € | 1 |
2020 Q3 | 18 611.22 € | 31 639.91 € | 8 975.45 € | - |
2020 Q2 | 10 371.21 € | 27 566.44 € | 7 055.59 € | - |
2020 Q1 | 121 375.1 € | 11 372.98 € | 641.14 € | - |